88784-36-5

Upstream product

• 138552-56-4 [3-(3-Methoxy-phenyl)-piperidin-1-yl]-phenyl-methanone 
• 626-55-1 3-Bromopyridine 
• 4373-67-5 3-(3-methoxyphenyl)pyridine 
• 2398-37-0 3-methoxyphenyl bromide 
• 40114-49-6 1-benzyl-3-piperidone 
• 87996-59-6 1-benzyl-3-(3-methoxy-phenyl)-piperidin-3-ol 
• 36282-40-3 (3-methoxyphenyl)magnesium bromide 

Downstream Products

• 79412-47-8 3-(1-Benzyl-piperidin-3-yl)-phenol; hydrobromide 
• 89920-95-6 N-benzyl-3(R)-(3-methoxyphenyl)piperidine 
• 19725-18-9 (+)-3-(3-methoxyphenyl)piperidine hydrochloride 

Relevant academic research and scientific papers

N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES

The invention relates to N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators having the general formula (1) or (2) and pharmaceutical preparations containing the said compounds. Further, the invention relates the use of the s

3-Phenylpiperidines. Central Dopamine-Autoreceptor Stimulating Activity

Thirty compounds related to the selective dopamine-autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine have been synthesized and tested for central dopamine-autoreceptor stimulating activity.The 3-(3-hydroxyphenyl)piperidine moiety seems indispensable for high potency and selectivity.Introduction of an additional hydroxyl group into the 4-position of the aromatic ring gives a compound with dopaminergic activity but lacking selectivity for autoreceptors. 3-(3-Hydroxyphenyl)-N-n-propylpyrrolidine, 3-(3-hydroxy)-N-n-propylperhydroazepine, and 3-(3-hydroxyphenyl)quinuclidine were all inactive.The most potent compounds were the N-isopropyl-, N-n-butyl-, N-n-pentyl-, and N-phenethyl-substituted 3-(3-hydroxyphenyl)piperidine derivatives.None of the compounds investigated seemed to have central noradrenaline- or serotonin-receptor stimulating activity.